HFS
CTKB icon

Hantz Financial Services’s Cytek Biosciences CTKB Stock Holding History

Hantz Financial Services’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1K Sell
133
-454
-77% -$1.94K ﹤0.01% 2358
2026
Q1 		$3K Buy
587
+298
+103% +$1.41K ﹤0.01% 2237
2025
Q4 		$1K Buy
+289
New +$1.34K ﹤0.01% 2311

Other funds holding CTKB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $386M AUM 2.37% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Hantz Financial Services's CTKB Position: Q2 2026 in Review

Hantz Financial Services reduced its Cytek Biosciences (CTKB) stake by 77% in Q2 2026, selling an estimated $1.94K and leaving 133 shares worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #2358.

Hantz Financial Services first reported a position in CTKB in Q4 2025 and has held it in 3 quarters since. The position peaked at $3K in Q1 2026. 155 funds tracked by Wall St. Rank hold CTKB as of Q2 2026.

  • Hantz Financial Services held 133 shares of Cytek Biosciences worth $1K as of Q2 2026.
  • Hantz Financial Services sold 454 Cytek Biosciences shares in Q2 2026, an estimated $1.94K.
  • Cytek Biosciences made up ﹤0.01% of Hantz Financial Services's portfolio in Q2 2026, its #2358 holding.
  • Hantz Financial Services first reported a position in Cytek Biosciences in Q4 2025 and has held it in 3 quarters since.
  • Hantz Financial Services's Cytek Biosciences position peaked at $3K in Q1 2026.
  • 155 funds tracked by Wall St. Rank held Cytek Biosciences as of Q2 2026.

Based on Hantz Financial Services's 13F filing for Q2 2026, filed 13 Aug 2026.